HeartFlow (HTFL) Shares Rise +54.4% in 30 Days Following Strong Q2 Results and Guidance Increase
Key Takeaways
- HeartFlow shares rose about 54.4% in the 30 days through the August 14, 2026 close, from $27.25 on July 15 to $42.08.
- The advance was led by second-quarter results: revenue of $64.1 million, up roughly 48% year over year, and an adjusted loss of $0.07 per share that beat consensus expectations for a wider loss.
- Management raised full-year 2026 revenue guidance to $246 million–$250 million, implying 40%–42% growth, and increased its gross-margin outlook.
- HTFL climbed 35.7% on August 14 alone, and multiple analysts raised price targets in response.
- The company is not yet profitable, leaving execution, valuation, and insider-selling trends as key watch items.
HeartFlow (HTFL) Company Overview and Market Position
HeartFlow, Inc. is a commercial-stage medical technology company headquartered in San Francisco, California. It uses artificial intelligence and computational fluid dynamics to convert a single coronary CT angiography (CCTA) scan into a personalized, three-dimensional model of a patient’s coronary arteries. The resulting analysis helps physicians quantify blood flow, identify blockages, and assess plaque burden and composition without invasive testing.
Its platform includes HeartFlow FFRCT Analysis, Plaque Analysis, and RoadMap Analysis, with a fourth product, PCI Planner, expected to launch in 2026. The company says its technology has been studied in more than 100 clinical studies involving over 130,000 patients and published in more than 600 peer-reviewed clinical publications. HeartFlow went public on Nasdaq in August 2025 and is followed by investors as an AI-enabled diagnostics name with a U.S. market opportunity it estimates at about $5 billion for its FFRCT and Plaque products.
HeartFlow (HTFL) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 days ended August 14, 2026, HTFL advanced about 54.4%, rising from a July 15 close of $27.25 to $42.08. Much of that gain came in a single session: the stock jumped 35.7% on August 14 following second-quarter results, on volume well above its typical daily average.
The broader trailing three-month trend has also been positive but more volatile. From a close of $28.32 on May 15, 2026, to the August 14 close of $42.08, the stock gained about 48.6%. Within that stretch, HTFL rallied into the mid-$30s in late June, pulled back into the low-to-mid $20s by late July, and then rebounded sharply in early-to-mid August. At $42.08, the stock sits near its 52-week high and above its 50-day and 200-day moving averages. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What Drove HTFL Stock Price in the Last 30 Days
The dominant catalyst was the company’s second-quarter 2026 report, released after the market closed on August 13. HeartFlow posted revenue of $64.08 million, up 47.7% year over year, and a narrower adjusted net loss of $0.07 per share. Adjusted EBITDA losses narrowed to $6.7 million from $10.1 million a year earlier, and the company reported record gross margin.
Management raised full-year 2026 revenue guidance to a range of $246 million to $250 million, up from $228 million to $232 million previously, implying about 40%–42% revenue growth, and lifted its gross-margin outlook to about 82%. Executives pointed to durable growth in the FFRCT business and accelerating Plaque Analysis adoption. On the other side, the company’s net loss widened to $15.7 million from $9.2 million a year earlier.
The report triggered a wave of analyst target increases. Stifel raised its price target to $45 from $40, JPMorgan moved to $45 from $35, and Wells Fargo lifted its target to $39 from $37, while Piper Sandler reiterated an Overweight rating. Institutional filings also showed increased fund ownership, adding to the supportive backdrop, though insider sales under pre-arranged trading plans remained a counterweight. From what I see, the earnings surprise and guidance lift were the main drivers here.
What Drove HTFL Stock Performance Over the Last Quarter
Over the trailing three months, HTFL’s gains reflect a re-rating of an AI-enabled medtech story that had largely traded sideways to down after its 2025 IPO. The FFRCT franchise provided stable volume growth, while Plaque Analysis emerged as a second growth engine and helped expand account utilization. Management commentary emphasized record gross margin and improving operating leverage, reinforcing the long-term profitability narrative.
The quarter was not a straight line higher. After a strong late-June run into the mid-$30s, shares pulled back through July and traded near the low-to-mid $20s before recovering in August. Hedge-fund data showed rising institutional participation earlier in 2026, and the August earnings beat and guidance raise ultimately validated the constructive view held by most covering analysts. I’m watching this closely as momentum builds.
HTFL Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on whether HeartFlow can sustain FFRCT volume growth, accelerate Plaque Analysis adoption, and deliver the newly raised revenue outlook. The planned 2026 launch of PCI Planner and new clinical studies in asymptomatic patients could expand the addressable market, while updates on gross margin and operating leverage will inform the path toward profitability.
Other watch items include analyst estimate revisions after the guidance increase, macroeconomic sensitivity typical of unprofitable growth companies, competitive developments in AI-enabled cardiac imaging, and ongoing insider-selling patterns disclosed in SEC filings. The company’s next quarterly report will be an important checkpoint for whether current momentum is being converted into sustained execution. One thing that stands out is the potential for further re-rating if execution remains strong.
Using AI Tools for Stock Analysis
In my research process, I occasionally review automated strategies on Tickeron’s Trending AI Robots page. It offers a curated selection of AI-powered trading bots from a platform that provides hundreds of bots trading thousands of tickers. Only top-performing and most relevant strategies appear, and the featured bots vary in approach, timeframe, and performance metrics. The page helps monitor currently favored strategies rather than offering a one-size-fits-all recommendation. Because performance varies, the featured selection can change over time, which is useful for staying informed on evolving approaches.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HTFL's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for HTFL moved into oversold territory on October 09, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on HTFL as a result. In 22 of 23 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
Following a +6.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 74 of 82 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 42 of 56 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for HTFL moved out of overbought territory on September 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In 3 of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 9 similar instances when the indicator turned negative. In 8 of the 9 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
HTFL broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.528) is normal, around the industry mean (7.432). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.656). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement